HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxytrol For Women Exclusivity Ends Not With Competition, But Label Warning Change

This article was originally published in The Tan Sheet

Executive Summary

Private labeler Perrigo has eyed launching a generic since FDA approved the 3.9mg oxybutynin transdermal as a first-in-class OTC in 2013. Currently, though, Perrigo says it is "not a big product" and is talking about other prescription OAB products that could be approved for OTC.

You may also be interested in...



Bayer Consumer Health Journey Still Short Of Destination

Bayer says issues encountered after acquiring Merck & Co.’s consumer brands two years ago have meant slower growth than expected. But it suggests that’s not a precedent for its planned mega-merger with Monsanto.

Bayer Consumer Health Journey Still Short Of Destination

Bayer says issues encountered after acquiring Merck & Co.’s consumer brands two years ago have meant slower growth than expected. But it suggests that’s not a precedent for its planned mega-merger with Monsanto.

Perrigo's 'Inversion' Of Flonase Trademark Cuts Too Close For Glaxo's Market Share Comfort

Glaxo says it distributed more than $330m in Flonase Allergy Relief in 2015, its first year available as the second-in-category corticosteroid nasal spray, but argues that Nasoflow, Perrigo's brand for a generic equivalent, unfairly will encroach on its sales and market share.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS108828

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel